Use of drug therapy to manage acute cutaneous necrosis of the skin

Journal of Drugs in Dermatology

Volumn 9, Issue 4, 2010, Pages 341-349

  Wallace, Jill S ^a   Hall, John C ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BCG VACCINE; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DOXYCYCLINE; ETANERCEPT; HEPARIN; HEPARINOID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; PROTEIN C; PROTEIN S; SPIDER VENOM; THROMBIN INHIBITOR; TUBERCULOSTATIC AGENT; WARFARIN;

ANTICOAGULATION; BACTERIAL INFECTION; BCG VACCINATION; BLOOD CLOTTING DISORDER; BURULI ULCER; CALCINOSIS; DEBRIDEMENT; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EARLY INTERVENTION; ECTHYMA GANGRENOSUM; ENDEMIC DISEASE; FULMINATING PURPURA; HUMAN; HYPERBARIC OXYGEN; NECROTIZING ARTERITIS; NECROTIZING FASCIITIS; PYODERMA GANGRENOSUM; REVIEW; SKIN BIOPSY; SKIN DISEASE; SKIN NECROSIS; SKIN SURGERY; SPIDER BITE; THROMBOCYTOPENIA; VASCULITIS; VIBRIO VULNIFICUS INFECTION; WEGENER GRANULOMATOSIS; ACUTE DISEASE; ARTICLE; NECROSIS; PATHOLOGY; SKIN;

ACUTE DISEASE; EARLY DIAGNOSIS; FASCIITIS, NECROTIZING; HUMANS; NECROSIS; PURPURA FULMINANS; PYODERMA GANGRENOSUM; SKIN; SKIN DISEASES; VASCULITIS;

EID: 77953624403     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg. 2000;87(3):266-272. (Pubitemid 30156350)
2. Brooks LW Jr, Blias FX. Coumadin-induced skin necrosis. J Am Osteopath Assoc. 1991;91(6)601-605.
3. Eby CS. Warfarin-induced skin necrosis. Hematol Oncol Clin North Am. 1993;7(6)1291-1300. (Pubitemid 24003282)
4. Miura Y, Ardenghy M, Ramasastry S, et al. Ann Plast Surg. 1996;37(3):332-337.
5. Gelwix TJ, Beeson MS. Warfarin-induced skin necrosis. Am J Emerg Med. 1998;16(5)541-543. (Pubitemid 28385629)
6. Nazarian R, Van Cott E, Zembowicz A, Duncan L. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61(2):325-332.
7. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg. 2000;87(3):266-272. (Pubitemid 30156350)
8. Lewandowski K, Zawilska K. Protein C concentrate in the treatment of warfarin-induced skin necrosis in the protein C deficiency. Thromb Haemost. 1994;71(3):395. (Pubitemid 24083752)
9. Jillella AP, Lutcher CL. Reinstituting warfarin in patients who develop warfarin skin necrosis. Am J Hematol. 1996;52(2)117-119. (Pubitemid 26175048)
10. Handschin AE, Trentz O, Kock HJ, Wanner GA. Low molecular weight heparin-induced skin necrosis: A systematic review. Langenbecks Arch Surg. 2005;390(3):249-254. (Pubitemid 40894629)
11. Balestra B. Skin necrosis: A paradoxical complication of anticoagulation. Schweiz Med Wochenschr. 1995;125(8):361-364.
12. White PW, Sadd Jr, Nensel RE. Thrombotic complications of heparin therapy: Including six cases of heparin-induced skin necrosis. Ann Surg. 1979;190(5):595-608. (Pubitemid 10213666)
13. Hall JC, McConahay D, Gibson D, et al. Heparin necrosis. An anticoagulation syndrome. JAMA. 1980;244(16):1831-1832. (Pubitemid 10004200)
14. Levine LE, Bernstein JE, Soltani K, et al. Heparin-induced cutaneous necrosis unrelated to injection sites. A sign of potentially lethal complications. Arch Dermatol. 1983;178(1):47-50.
15. Rongioletti F, Pisani S, Ciaccio M, Rebora A. Skin necrosis due to intravenous heparin. Dermatologica. 1989;178(1)47-50. (Pubitemid 19051535)
16. Handschin E, Trentz O, Kock H, Wanner A. Low molecular weight heparin-induced skin necrosis - A systematic review. Langenbecks Arch Surg. 2005;390:249-254. (Pubitemid 40894629)
17. Leblanc M, Roy LR, Legault L, et al. Severe skin necrosis associated with heparin in hemodialysis. Nephron. 1994;68(1):133-137. (Pubitemid 24251201)
18. Mar AW, Dixon B, Ibrahim K, Parkin JD. Skin necrosis following subcutaneous heparin injection. Australas J Dermatol. 1995;36(4):201-203.
19. Fowlie J, Stanton PD, Anderson JF. Heparin-associated skin necrosis. Postgrad Med J. 1990;66(777):573-575. (Pubitemid 20208054)
20. Wright SW, Wrenn KD, Murray L, Seger D. Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med. 1997;30(1):28-32. (Pubitemid 27283933)
21. Anderson PC. Missouri brown recluse spider bite: A review and update. Mo Med. 1998;95(7):318-322.
22. Furbee R, Kao L, Ibrahim D. Brown recluse spider envenomation. Clin Lab Med. 2006;26:211-226.
23. Swanson D, Vetter R. Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med. 2005;352:700-707. (Pubitemid 40239218)
24. Swanson DL, Vetter RS. Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med. 2005;352(7):700-707. (Pubitemid 40239218)
25. Sarani B, Strong M, Pascual J, Schwab W. Necrotizing fasciitis: Current concepts and review of the literature. J Amer Col Surg. 2009;208(2):279-288.
26. Kihiczak GG, Schwartz RA, Kapila R. Necrotizing fasciitis: A deadly infection. Eur Acad Dermatol Venerol. 2006;20:365-369.
27. Lopez FA, Lartchenko S. Skin and soft tissue infections. Infec Dis Clinics North Amer. 2006;20(4):759-772. (Pubitemid 44752024)
28. Cartwright K, Logan M, McNulty C et al. A cluster of cases of streptococcal necrotizing fasciitis in Gloucestershire. Epidemiol Infect. 1995;115(3):387-397. (Pubitemid 26025313)
29. Jallali N. Necrotising fasciitis: Its aetiology, diagnosis and management. J Wound Care. 2003;12(8):297-300.
30. McGee EJ. Necrotizing fasciitis: Review of pathophysiology, diagnosis, and treatment. Crit Care Nurs Q. 2005;28(1):80-84. (Pubitemid 40175836)
31. Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: Current concepts and review of the literature. J Am Coll Surg. 2009;208(2):279-288.
32. Simonart T, Nakafusa J, Narisawa Y. The importance of serum creatinine phosphokinase level in the early diagnosis and microbiological evaluation of necrotizing fasciitis. J Eur Acad Dermatol Venereol. 2004;18(6):687-690. (Pubitemid 39429708)
33. Clark P, Davidson D, Letts M, et al. Necrotizing fasciitis secondary to chickenpox infection in children. Can J Surg. 2003;46(1):9-14. (Pubitemid 36245397)
34. Rosefsky JB. Varicella and necrotizing fasciitis. Pediatr Infect Dis J. 1996;15(6):556-557. (Pubitemid 26187811)
35. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal anti-inflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine Baltimore. 2003;82(4):225-235. (Pubitemid 36859218)
36. Allen NB, Bressler PB. Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndrome. Med Clin North Am. 1997;81(1):243-259. (Pubitemid 27043803)
37. Guillevin L. Immunosuppressants in systemic necrotizing vasculidities. Isr Med Assoc J. 2001;3(10):749-754.
38. Guillevin L. Therapeutic strategies in systemic necrotizing vasculidities. Acta Clin Belg. 2001;56(2):103-112. (Pubitemid 32417143)
39. Guillevin L. Treatment of systemic necrotizing vasculitis. Rev Med Interne. 2002;23 Suppl 5:554s-558s.
40. Calabrese LH, Hoffman GS, Guillevin L. Therapy of resistant systemic necrotizing vasculitis. Polyarteritis, Churg-Strauss syndrome, Wegener's granulomatosis, and hypersensitivity vasculitis group disorders. Rheum Dis Clin North Am. 1995;21(1):41-57.
41. Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. Evaluation of a new algorithm in classification of systemic vasculitis. Rheum Oxford. 2008;47(5):708-712. (Pubitemid 351619217)
42. Wollina U. Pyoderma gangrenosum - A review. Orphanet J Rare Diseases. 2007;19(2).
43. Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: Clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790-800. (Pubitemid 39529936)
44. Powell FC, O'Kane M. Management of pyoderma gangrenosum. Dermatol Clin. 2002;20(2):347-355. (Pubitemid 34685735)
45. Gettler S, Rothe M, Grin C, Grant-Kels J. Optimal treatment of pyoderma gangrenosum. Am J Clin Dermatol. 2003;4(9):597-608. (Pubitemid 37108419)
46. Ehling A, Karrer S, Klebl F, et al. Therapeutic management of pyoderma gangrenosum. Arthritis Rheum. 2004;50(10):3076-3084. (Pubitemid 39371982)
47. Wenzel J, Gerson R, Phillip-Dormston W, Bieber T, Uerlich M. Topical treatment of pyoderma gangrenosum. Dermatology. 2002;205(3):221-223.
48. Molos MA, Hall JC. Symmetrical peripheral gangrene and disseminated intravascular coagulation. Arch Dermatol. 1985;121(8):1057-1061. (Pubitemid 15014951)
49. Sharma BD, Kabra SR, Gupta B. Symmetrical peripheral gangrene. Trop Doct. 2004;34(1):2-4. (Pubitemid 38168061)
50. Hodge SJ. Purpura fulminans. Cutis. 1978;21(6)830-832. (Pubitemid 8358559)
51. Lalitha AV, Aruna D, Prakash A, et al. Spectrum of purpura fulminans. Indian J Pediatr. 2009;76(1):87-89.
52. Gürses N, Ozkan A. Neonatal and childhood purpura fulminans: Review of seven cases. Cutis. 1988;41(5)361-363.
53. Sen K, Roy A. Management of neonatal purpura fulminans with severe protein C deficiency. Indian Pediatr. 2006;43(6):542-545. (Pubitemid 44049658)
54. Bruun CF, Langbakk B, ErikssonSteigen S. Purpura fulminans as a sequel to erythema nodosum in a child with homozygous Leiden mutation and acquired protein S deficiency. Acta Paediatr. 2005;94(8):1155-1158. (Pubitemid 41169672)
55. Warner PM, Kagan RJ, Yakuboff KP, et al. Current management of purpura fulminans: A multicenter study. J Burn Care Rehabil. 2003;24(3):119-126. (Pubitemid 36604419)
56. Krzelj V, Petri NM, Mestrovic J, et al. Purpura fulminans successfully treated with hyperbaric oxygen - A report of 2 cases. Pediatr Emerg Care. 2005;21(1):31-34. (Pubitemid 40130233)
57. Seipelt H, Von Mühlendahl KE, Hoy M. Purpura fulminans - Aspects of etiopathogenesis, clinical aspects, diagnosis and therapy. Z Artzl Fortbid (Jena). 1991;85(19)970-912.
58. Silbart S, Oppenheirn W. Purpura fulminans. Medical, surgical and rehabilitative considerations. Clin Orthop Relat Res. 1985;(193):206-213. (Pubitemid 15132197)
59. Kuzemko JA, Loder RE. Purpura fulminans treated with hyperbaric oxygen. Br Med J. 1970;4(728):157.
60. Chu DZ, Blaisdell FW. Am J Surg. 1982;143(3):356-362.
61. Smith OP, White B, Vaughan D et al. Use of protein C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet. 1997;350(9091):1590-1593. (Pubitemid 28036602)
62. Obara Y, Nagal T, Mori M, et al. Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient. Rinsho Ketsueki. 2004;45(10):1138-1140.
63. Oh DH, Eulau D, Tokugawa DA, et al. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol. 1999;40(6 Pt 1):979-987. (Pubitemid 29268930)
64. Trent JT, Kirsner RS. Calciphylaxis: Diagnosis and treatment. Adv Skin Wound Care. 2001;14(6):309-312.
65. Beus KS, Stack BC Jr. Calciphylaxis. Otolaryngol Clin North Am. 2004;37(4)941-948. (Pubitemid 38950698)
66. Reed KB, Davis MD. The incidence of physician-diagnosed calciphylaxis: A population-based study. J Am Acad Dermatol. 2007;57(2):365-366. (Pubitemid 47048865)
67. Bleyer AJ, Choi M, Igwemezie B, De la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32(3):376-383. (Pubitemid 28411209)
68. Borenstein M, Kerdel F. Infections with Vibrio vulnificus. Dermatol Clin. 2003;21(2):245-248. (Pubitemid 36529757)
69. Chiang SR, Chuang YC. Vibrio vulnificus infection: Clinical manifestations, pathogenesis and antimicrobial therapy. J Microbiol Immunol Infect. 2003;36(2):81-88.
70. Kumamoto KS, Vikich DJ. Clinical infections of Vibrio vulnificus: A case report and review of the literature. J Emerg Med. 1998;16(1):61-66. (Pubitemid 28087351)
71. Bross MH, Soch K, Morales R, Mitchell RB. Vibrio vulnificus infections, diagnosis, and treatment. Amer Fam Phys. 2007;76(4):539-544.
72. Tang HJ, Chang MC, Ko WC, et al. In vitro and in vivo activities of new fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother. 2002;45(11):3580-3584.
73. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol. 2009;27(3):291-305.
74. Van der Werf TS, Van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet. 1999;354(9183):1013-1018. (Pubitemid 29438417)
75. Huygen K. Prospects for vaccine development against Buruli disease. Expert Rev Vaccines. 2003;2(4):561-569. (Pubitemid 36988486)
76. Thangaraj HS, Phillips RO, Evans MR, Wansbrough-Jones MH. Emerging aspects of Buruli ulcer. Expert Rev Anti Infect Ther. 2003;1(2):217-222. (Pubitemid 38855085)
77. Nackers F, Dramiax M, Johnson RC, et al. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg. 2006;75(4):768-774. (Pubitemid 46941291)
78. Funabiki K, Masuoka H, Shimizu H, et al. Cholesterol crystal embolization (CCE) after cardiac catheterization: A case report and review of 36 cases in the Japanese literature. Jpn Heart J. 2003;44(5):767-774. (Pubitemid 41518977)
79. Bashore TM, Gehrig T. Cholesterol emboli after invasive cardiac procedures. J Am Coll Cardiol. 2003;42(2):217-218. (Pubitemid 36851408)
80. Fukumoto Y, Tsutsui H, Tsuchihashi M, et al. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: A prospective study. J Am Coll Cardiol. 2003;42(2):211-216. (Pubitemid 36851407)
81. Stewart WM, Laurer P, Testart J, et al. Cutaneous cholesterol emboli (author's transl). Ann Dermatol Venereol. 1977;104(1):5-8.
82. Baumann DS, McGraw D, Rubin BG, et al. An institutional experience with arterial atheroembolism. Ann Vasc Surg. 1994;8(3):258-265. (Pubitemid 24164863)
83. Hendel RC, Cuenoud HF, Giansiracusa DF, Alpert JS. Multiple cholesterol emboli syndrome. Bowel infarction after retrograde angiography. Arch Intern Med. 1989;149(10):2371-2374. (Pubitemid 19258187)
84. Hitti WA, Wali RK, Weinman EJ, et al. Cholesterol embolization syndrome induced by thrombolytic therapy. Am J Cardiovasc Drugs. 2008;8(1):27-34.
85. Garcia DA, Khamashta MA, Crowther MA. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood. 2007;110(9):3122-3127. (Pubitemid 350106302)
86. Rodriguez Jornet A, Andreu FJ, Tolosa C. 40-year-old man with primary antiphospholipid syndrome. Nefrologia. 2002;22(5):477-481.
87. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res. 2005;115(1-2):3-8. (Pubitemid 39572748)
88. Khor B, Van Cott EM. Laboratory evaluation of hypercoagulability. Hemostasis Coag. 2009;29(2):339-366.
89. George D, Erkan D. Antiphospholipid syndrome. Progress in Cardio Dis. 2009;52(2):115-125.
90. Asherson RA. The catastrophic antiphospholipid (Asherton's) syndrome in 2004 - A review. Autoimmune Rev. 2005;4(1):48-54. (Pubitemid 40126372)